Merck dans l'actualité
La science de pointe sauve des vies
Tamtam a trouvé 20 articles récents sur Merck.
- Merck’s injectable Keytruda barred in Europe (MRK:NYSE)
- Merck’s New Keytruda Shot Blocked in Europe After Court Loss
- Dutch court bars Merck's Keytruda SC in eight European markets in Halozyme patent case
- Tempus Announces Multi-Year Collaboration with Moderna and Merck
- Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
- Better Dividend for Retirees: AbbVie vs. Merck
- Merck price target raised to $165 from $150 at JPMorgan
- Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
- Merck business unit opens R&D facility in Sheboygan Falls
- Moderna, Merck Rally On Cancer Vaccine Promise. But Is The Multi-Billion-Dollar Hype Real?
- Moderna Soars On Cancer Vaccine. Is mRNA Ready For Prime Time?
- Merck’s anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial
- Why Merck (MRK) Dipped More Than Broader Market Today
- Why Merck (MRK) Dipped More Than Broader Market Today
- Merck pulls antibiotic for multidrug-resistant infections from US market
- Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
- AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech
- Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue
- Merck pulls antibiotic from US market
- Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Merck ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires